fenofibrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
clofibrate derivatives, peroxisome proliferator activated receptor-alpha(PPAR-alpha) agonists 1152 49562-28-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fenofibrate
  • clorofibrate
  • fenobrate
  • lipofene
  • procetofen
  • procetofene
An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
  • Molecular weight: 360.83
  • Formula: C20H21ClO4
  • CLOGP: 5.23
  • LIPINSKI: 1
  • HAC: 4
  • HDO: 0
  • TPSA: 52.60
  • ALOGS: -5.71
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.74 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1993 FDA ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 233.75 10.66 201 36369 40457 56215040
Blood triglycerides increased 191.89 10.66 110 36460 11567 56243930
Pancreatitis acute 183.90 10.66 143 36427 24981 56230516
Acute kidney injury 163.32 10.66 431 36139 240332 56015165
Pancreatitis 156.77 10.66 169 36401 44911 56210586
Rheumatoid arthritis 125.52 10.66 46 36524 382558 55872939
Myalgia 121.28 10.66 266 36304 131759 56123738
Hypertriglyceridaemia 101.50 10.66 57 36513 5759 56249738
High density lipoprotein decreased 89.30 10.66 36 36534 1726 56253771
Contraindicated product administered 86.26 10.66 10 36560 186276 56069221
Blood creatine phosphokinase increased 85.46 10.66 98 36472 27854 56227643
Pemphigus 82.18 10.66 5 36565 157207 56098290
International normalised ratio increased 77.91 10.66 118 36452 43923 56211574
Systemic lupus erythematosus 75.57 10.66 13 36557 180065 56075432
Hand deformity 74.36 10.66 3 36567 134489 56121008
Glossodynia 73.61 10.66 7 36563 152451 56103046
Treatment failure 72.17 10.66 12 36558 170380 56085117
Renal failure 71.86 10.66 195 36375 110305 56145192
Drug ineffective 68.24 10.66 337 36233 918652 55336845
Maternal exposure during pregnancy 65.14 10.66 21 36549 189532 56065965
Infusion related reaction 57.64 10.66 32 36538 208899 56046598
Drug interaction 56.04 10.66 277 36293 209478 56046019
Pericarditis 55.33 10.66 4 36566 108919 56146578
Wound 54.06 10.66 12 36558 138792 56116705
Joint swelling 53.29 10.66 66 36504 289734 55965763
Therapeutic product effect decreased 51.18 10.66 23 36547 169429 56086068
Confabulation 50.15 10.66 15 36555 289 56255208
Blood glucose increased 48.21 10.66 132 36438 75019 56180478
Hepatic function abnormal 48.03 10.66 83 36487 34475 56221022
Arthropathy 46.70 10.66 37 36533 200238 56055259
Myocardial infarction 42.58 10.66 145 36425 92725 56162772
Skin weeping 41.80 10.66 15 36555 521 56254976
Off label use 41.05 10.66 204 36366 555976 55699521
Glycosylated haemoglobin increased 40.80 10.66 43 36527 11122 56244375
Rectosigmoid cancer 40.39 10.66 11 36559 149 56255348
Coronary artery disease 40.25 10.66 72 36498 30724 56224773
Abdominal discomfort 39.57 10.66 75 36495 277199 55978298
Hepatorenal failure 39.50 10.66 15 36555 612 56254885
Product use issue 38.99 10.66 38 36532 186003 56069494
Jaundice 38.51 10.66 66 36504 27228 56228269
Alopecia 37.96 10.66 84 36486 293374 55962123
Swelling 37.70 10.66 61 36509 239710 56015787
Myoglobin blood increased 37.09 10.66 18 36552 1346 56254151
Lichenoid keratosis 36.35 10.66 18 36552 1407 56254090
Nephrosclerosis 35.98 10.66 16 36554 980 56254517
Hepatic steatosis 35.17 10.66 62 36508 26152 56229345
Hypertonic bladder 34.16 10.66 23 36547 3209 56252288
Hyperglycaemia 32.69 10.66 75 36495 38206 56217291
Fall 32.50 10.66 365 36205 357145 55898352
Lichen nitidus 32.35 10.66 8 36562 72 56255425
Alkalosis hypochloraemic 32.07 10.66 9 36561 137 56255360
Cholestasis 31.49 10.66 60 36510 26853 56228644
Photosensitivity reaction 30.79 10.66 41 36529 13552 56241945
Apolipoprotein A-I decreased 29.25 10.66 6 36564 20 56255477
Infection 27.80 10.66 55 36515 200151 56055346
Myopathy 27.64 10.66 33 36537 9779 56245718
Kidney fibrosis 27.52 10.66 16 36554 1726 56253771
Hypersensitivity 27.28 10.66 81 36489 256327 55999170
Diabetes mellitus 26.53 10.66 85 36485 52650 56202847
Lower respiratory tract infection 25.76 10.66 22 36548 114772 56140725
Lactic acidosis 25.62 10.66 65 36505 35281 56220216
Dilatation ventricular 25.58 10.66 17 36553 2321 56253176
Hypoglycaemia 25.44 10.66 87 36483 55728 56199769
Stomatitis 24.92 10.66 25 36545 120785 56134712
Change of bowel habit 24.84 10.66 16 36554 2073 56253424
Multiple fractures 24.59 10.66 27 36543 7314 56248183
Discomfort 24.26 10.66 34 36536 141727 56113770
Dyslipidaemia 24.17 10.66 25 36545 6328 56249169
Congestive hepatopathy 24.09 10.66 17 36553 2559 56252938
Drug abuse 24.09 10.66 7 36563 67603 56187894
Diabetes mellitus inadequate control 24.06 10.66 37 36533 13943 56241554
Cholelithiasis 23.99 10.66 68 36502 39396 56216101
Narcotic bowel syndrome 23.95 10.66 7 36563 124 56255373
Arterial spasm 23.69 10.66 6 36564 60 56255437
Ocular icterus 23.35 10.66 19 36551 3537 56251960
Psoriasis 23.01 10.66 120 36450 92572 56162925
Chronic cutaneous lupus erythematosus 22.94 10.66 8 36562 255 56255242
Blood creatinine increased 22.88 10.66 108 36462 80083 56175414
Pulmonary embolism 22.79 10.66 133 36437 106991 56148506
Myotonia 22.70 10.66 7 36563 150 56255347
Mucosal dryness 22.24 10.66 16 36554 2482 56253015
Hepatic necrosis 22.19 10.66 22 36548 5294 56250203
Hyperlipidaemia 21.96 10.66 41 36529 18068 56237429
Irritable bowel syndrome 21.11 10.66 9 36561 68449 56187048
Orthopnoea 20.54 10.66 22 36548 5794 56249703
Hepatic fibrosis 20.29 10.66 17 36553 3295 56252202
Normochromic normocytic anaemia 20.04 10.66 19 36551 4330 56251167
Ophthalmoplegia 19.92 10.66 12 36558 1381 56254116
Asthenia 19.52 10.66 322 36248 342651 55912846
Aortic arteriosclerosis 19.36 10.66 21 36549 5609 56249888
Musculoskeletal stiffness 19.06 10.66 46 36524 155961 56099536
Impaired healing 19.05 10.66 17 36553 86824 56168673
Wheezing 18.58 10.66 13 36557 75013 56180484
Grandiosity 18.33 10.66 7 36563 290 56255207
Product residue present 18.29 10.66 17 36553 3778 56251719
Somnolence 18.20 10.66 174 36396 163239 56092258
Blood triglycerides abnormal 18.20 10.66 7 36563 296 56255201
Ill-defined disorder 18.16 10.66 11 36559 68532 56186965
Catheter site thrombosis 18.08 10.66 6 36564 164 56255333
Vulvovaginal burning sensation 17.90 10.66 12 36558 1662 56253835
Mobility decreased 17.68 10.66 23 36547 98968 56156529
Renal impairment 17.68 10.66 101 36469 80612 56174885
Drug intolerance 17.32 10.66 101 36469 264717 55990780
Gastrointestinal haemorrhage 17.27 10.66 96 36474 75855 56179642
Low density lipoprotein increased 16.95 10.66 20 36550 5854 56249643
Vulvovaginal pruritus 16.71 10.66 14 36556 2714 56252783
Mitral valve disease 16.54 10.66 13 36557 2304 56253193
Chromaturia 16.51 10.66 33 36537 15292 56240205
Gastrointestinal disorder 16.48 10.66 30 36540 112672 56142825
Diabetic metabolic decompensation 16.32 10.66 11 36559 1537 56253960
Exposure during pregnancy 16.02 10.66 41 36529 136301 56119196
Medulloblastoma 15.89 10.66 4 36566 39 56255458
Intra-abdominal haematoma 15.54 10.66 11 36559 1663 56253834
Hepatocellular injury 15.45 10.66 45 36525 26469 56229028
Essential hypertension 15.27 10.66 17 36553 4676 56250821
Abnormal loss of weight 15.17 10.66 18 36552 5298 56250199
Hyperkalaemia 14.86 10.66 69 36501 50796 56204701
Xanthoma 14.70 10.66 4 36566 54 56255443
Nasopharyngitis 14.58 10.66 84 36486 220875 56034622
Nicotinic acid deficiency 14.37 10.66 4 36566 59 56255438
Metabolic acidosis 14.21 10.66 58 36512 40396 56215101
Alanine aminotransferase 14.19 10.66 4 36566 62 56255435
Rhinalgia 14.18 10.66 9 36561 1136 56254361
Coronary artery occlusion 14.07 10.66 21 36549 7708 56247789
Blood triglycerides decreased 14.07 10.66 4 36566 64 56255433
Product use in unapproved indication 13.89 10.66 46 36524 140776 56114721
Cardiac failure congestive 13.82 10.66 101 36469 87619 56167878
Pain 13.81 10.66 327 36243 662857 55592640
Blood urea increased 13.75 10.66 41 36529 24432 56231065
Peripheral swelling 13.55 10.66 93 36477 234633 56020864
Muscle contracture 13.50 10.66 9 36561 1235 56254262
Dehydration 12.98 10.66 159 36411 158666 56096831
Haematoma muscle 12.91 10.66 8 36562 969 56254528
Muscle spasms 12.77 10.66 141 36429 137230 56118267
Dermatomyositis 12.75 10.66 12 36558 2710 56252787
Polymyositis 12.73 10.66 10 36560 1770 56253727
Livedo reticularis 12.73 10.66 11 36559 2224 56253273
Blood glucose decreased 12.70 10.66 34 36536 19053 56236444
Proteinuria 12.41 10.66 32 36538 17538 56237959
Coagulation test abnormal 12.39 10.66 7 36563 715 56254782
Aspartate aminotransferase 12.35 10.66 4 36566 101 56255396
Chronic kidney disease 12.25 10.66 57 36513 41999 56213498
Renin decreased 12.24 10.66 4 36566 104 56255393
Auditory disorder 12.13 10.66 6 36564 468 56255029
Depression 12.10 10.66 174 36396 179943 56075554
Thirst 12.09 10.66 24 36546 11066 56244431
Arthralgia 11.97 10.66 242 36328 501427 55754070
Cholecystitis acute 11.89 10.66 19 36551 7397 56248100
Lipids increased 11.80 10.66 8 36562 1129 56254368
Oedema peripheral 11.72 10.66 166 36404 171088 56084409
Blood cholesterol increased 11.68 10.66 84 36486 72495 56183002
Hyponatraemia 11.48 10.66 109 36461 102030 56153467
Anhedonia 11.47 10.66 22 36548 9892 56245605
Cholecystitis infective 11.46 10.66 9 36561 1593 56253904
Hepatic enzyme increased 11.39 10.66 65 36505 171319 56084178
Macule 11.19 10.66 9 36561 1648 56253849
Cerebrovascular accident 11.19 10.66 106 36464 99164 56156333
Vitamin B12 deficiency 11.12 10.66 14 36556 4379 56251118
Death 10.96 10.66 156 36414 341270 55914227
Pancoast's syndrome 10.73 10.66 3 36567 45 56255452
Blood phosphorus increased 10.70 10.66 11 36559 2765 56252732
Multiple injuries 10.69 10.66 9 36561 1757 56253740

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis acute 253.39 11.06 222 36815 25378 31634929
High density lipoprotein decreased 176.26 11.06 82 36955 3068 31657239
Blood triglycerides increased 150.52 11.06 125 36912 13272 31647035
Hypertriglyceridaemia 146.39 11.06 99 36938 7699 31652608
Pancreatitis 145.91 11.06 194 36843 35577 31624730
Myocardial infarction 90.65 11.06 315 36722 113139 31547168
Myalgia 88.21 11.06 243 36794 77015 31583292
Blood creatine phosphokinase increased 88.08 11.06 168 36869 41806 31618501
Coronary artery disease 87.67 11.06 177 36860 45910 31614397
Off label use 65.57 11.06 199 36838 347075 31313232
Rhabdomyolysis 63.83 11.06 191 36846 63390 31596917
Drug abuse 58.81 11.06 15 37022 87743 31572564
Pericardial disease 51.59 11.06 19 37018 387 31659920
Toxicity to various agents 51.43 11.06 83 36954 181404 31478903
Stenosis 48.33 11.06 25 37012 1180 31659127
Pulmonary valve disease 48.16 11.06 17 37020 305 31660002
Hyperlipidaemia 45.56 11.06 66 36971 13094 31647213
Drug-induced liver injury 44.44 11.06 92 36945 24271 31636036
Hepatic steatosis 41.70 11.06 71 36966 16168 31644139
Ependymoma 41.54 11.06 11 37026 69 31660238
Blood cholesterol increased 40.95 11.06 72 36965 16821 31643486
Death 40.19 11.06 252 36785 360317 31299990
Physical examination abnormal 34.37 11.06 13 37024 286 31660021
Glycogen storage disease type V 32.43 11.06 8 37029 36 31660271
Blood glucose increased 31.39 11.06 148 36889 60935 31599372
Fibrillary glomerulonephritis 30.95 11.06 8 37029 45 31660262
Diabetic metabolic decompensation 30.86 11.06 21 37016 1648 31658659
Renal failure 29.80 11.06 246 36791 123084 31537223
Cardiac discomfort 29.66 11.06 14 37023 541 31659766
Cholelithiasis 29.21 11.06 68 36969 19411 31640896
Subacute kidney injury 28.77 11.06 5 37032 0 31660307
Glycosylated haemoglobin increased 28.74 11.06 47 36990 10353 31649954
Echocardiogram abnormal 28.12 11.06 16 37021 914 31659393
Acute kidney injury 27.86 11.06 470 36567 279244 31381063
Metabolic syndrome 27.33 11.06 19 37018 1544 31658763
Myopathy 27.27 11.06 47 36990 10805 31649502
Pancreatic neoplasm 26.35 11.06 15 37022 858 31659449
Acute myocardial infarction 26.00 11.06 123 36914 50700 31609607
Ischaemic cardiomyopathy 25.59 11.06 33 37004 5864 31654443
Pancreatitis necrotising 25.57 11.06 22 37015 2449 31657858
Intentional overdose 24.25 11.06 9 37028 41380 31618927
Ventricular arrhythmia 23.82 11.06 29 37008 4862 31655445
Rales 23.82 11.06 39 36998 8600 31651707
Mitral valve disease 23.61 11.06 16 37021 1247 31659060
Dyslipidaemia 23.45 11.06 33 37004 6373 31653934
Ectopic gastric mucosa 23.29 11.06 5 37032 10 31660297
Chest pain 22.96 11.06 223 36814 116734 31543573
Low density lipoprotein increased 22.84 11.06 26 37011 4062 31656245
Rheumatoid arthritis 22.51 11.06 14 37023 47795 31612512
Blood triglycerides abnormal 22.04 11.06 9 37028 244 31660063
Drug ineffective 21.95 11.06 328 36709 395245 31265062
Left ventricular dysfunction 21.54 11.06 39 36998 9318 31650989
Electrocardiogram Q wave abnormal 21.17 11.06 10 37027 387 31659920
Euglycaemic diabetic ketoacidosis 20.86 11.06 21 37016 2853 31657454
Hepatojugular reflux 20.62 11.06 11 37026 553 31659754
Tricuspid valve incompetence 20.58 11.06 37 37000 8792 31651515
Diabetic neuropathy 20.19 11.06 24 37013 3925 31656382
Liver disorder 19.89 11.06 78 36959 29629 31630678
Anticoagulation drug level above therapeutic 19.68 11.06 17 37020 1902 31658405
Blood creatinine increased 19.56 11.06 174 36863 88904 31571403
Haemorrhagic fever 19.52 11.06 5 37032 27 31660280
Gamma-glutamyltransferase increased 19.40 11.06 74 36963 27751 31632556
Occult blood 19.09 11.06 11 37026 644 31659663
Diastolic dysfunction 18.82 11.06 27 37010 5308 31654999
Libido disorder 18.59 11.06 8 37029 248 31660059
Carotid artery stenosis 18.59 11.06 25 37012 4627 31655680
Meningitis streptococcal 18.41 11.06 5 37032 35 31660272
Muscle spasms 17.97 11.06 139 36898 68179 31592128
Mitral valve incompetence 17.86 11.06 46 36991 13987 31646320
Treatment failure 17.79 11.06 13 37024 40779 31619528
Diabetes mellitus inadequate control 17.51 11.06 43 36994 12698 31647609
Chromaturia 17.35 11.06 44 36993 13254 31647053
Cytomegalovirus infection 16.97 11.06 4 37033 24703 31635604
Chondrocalcinosis 16.95 11.06 8 37029 309 31659998
Cardiac failure congestive 16.88 11.06 154 36883 79233 31581074
Sleep apnoea syndrome 16.85 11.06 54 36983 18571 31641736
Bundle branch block left 16.71 11.06 26 37011 5492 31654815
Foetal exposure during pregnancy 16.60 11.06 14 37023 40862 31619445
Type 2 diabetes mellitus 16.34 11.06 46 36991 14738 31645569
Platelet count decreased 16.27 11.06 70 36967 110365 31549942
Breast cyst 16.04 11.06 4 37033 19 31660288
Asthenia 15.98 11.06 359 36678 224396 31435911
Intraocular pressure decreased 15.79 11.06 5 37032 63 31660244
Thrombocytopenia 15.70 11.06 100 36937 142647 31517660
Renal impairment 15.66 11.06 162 36875 86187 31574120
Hepatitis acute 15.49 11.06 28 37009 6681 31653626
Supraventricular tachycardia 15.47 11.06 36 37001 10271 31650036
Diabetic ketoacidosis 15.28 11.06 49 36988 16856 31643451
Glutamate dehydrogenase increased 15.18 11.06 3 37034 3 31660304
Product use in unapproved indication 15.14 11.06 62 36975 99109 31561198
Helicobacter gastritis 15.08 11.06 12 37025 1198 31659109
Obesity 14.76 11.06 37 37000 11063 31649244
Testicular oedema 14.75 11.06 5 37032 79 31660228
Systolic dysfunction 14.75 11.06 16 37021 2370 31657937
Ketonuria 14.74 11.06 9 37028 586 31659721
Chronic kidney disease 14.65 11.06 85 36952 37890 31622417
Intentional product use issue 14.48 11.06 22 37015 49325 31610982
Angiopathy 14.16 11.06 20 37017 3875 31656432
Erectile dysfunction 14.11 11.06 52 36985 19183 31641124
Retinal vein occlusion 14.03 11.06 13 37024 1594 31658713
Diet noncompliance 13.74 11.06 6 37031 193 31660114
Hepatic enzyme increased 13.61 11.06 80 36957 35828 31624479
Weight decreased 13.47 11.06 262 36775 159690 31500617
Cerebrovascular accident 13.42 11.06 147 36890 79337 31580970
Lipase increased 13.40 11.06 31 37006 8812 31651495
Procedural haemorrhage 13.35 11.06 15 37022 2309 31657998
Respiratory failure 13.35 11.06 67 36970 101382 31558925
Respiratory arrest 13.34 11.06 7 37030 26250 31634057
Leukopenia 13.23 11.06 30 37007 57798 31602509
Coma acidotic 13.11 11.06 3 37034 9 31660298
Serotonin syndrome 12.97 11.06 3 37034 18770 31641537
Optic neuropathy 12.83 11.06 13 37024 1780 31658527
Sepsis 12.65 11.06 115 36922 151814 31508493
Pyrexia 12.63 11.06 265 36772 303575 31356732
Cardiomyopathy 12.57 11.06 43 36994 15290 31645017
Angina unstable 12.53 11.06 35 37002 11160 31649147
Asthma 12.50 11.06 19 37018 42592 31617715
Loss of personal independence in daily activities 12.35 11.06 9 37028 28279 31632028
Malignant neoplasm progression 12.30 11.06 49 36988 78949 31581358
Drug resistance 12.30 11.06 6 37031 23447 31636860
Lung disorder 12.25 11.06 72 36965 32240 31628067
Coronary artery occlusion 12.21 11.06 33 37004 10323 31649984
Loss of bladder sensation 12.18 11.06 4 37033 57 31660250
Glucose tolerance impaired 12.17 11.06 16 37021 2896 31657411
Blood cholesterol abnormal 12.03 11.06 12 37025 1613 31658694
Fanconi syndrome 11.80 11.06 12 37025 1650 31658657
Psoriasis 11.70 11.06 94 36943 46625 31613682
Papillary renal cell carcinoma 11.62 11.06 5 37032 155 31660152
Febrile neutropenia 11.60 11.06 89 36948 121760 31538547
Radicular pain 11.32 11.06 4 37033 72 31660235
Medulloblastoma 11.27 11.06 4 37033 73 31660234
Retinal disorder 11.24 11.06 9 37028 906 31659401
Carotid arteriosclerosis 11.24 11.06 12 37025 1745 31658562
Blood glucose decreased 11.14 11.06 36 37001 12435 31647872
Abdominal pain upper 11.09 11.06 119 36918 63883 31596424

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis acute 385.96 10.17 312 58760 44912 70824460
Hypertriglyceridaemia 249.76 10.17 143 58929 11668 70857704
Blood triglycerides increased 246.71 10.17 171 58901 19493 70849879
Rhabdomyolysis 234.79 10.17 341 58731 95419 70773953
High density lipoprotein decreased 230.68 10.17 97 58975 4022 70865350
Pancreatitis 229.64 10.17 272 58800 62396 70806976
Acute kidney injury 167.87 10.17 810 58262 473814 70395558
Myalgia 151.43 10.17 391 58681 167501 70701871
Myocardial infarction 138.89 10.17 384 58688 171261 70698111
Blood creatine phosphokinase increased 134.12 10.17 207 58865 61056 70808316
Coronary artery disease 130.43 10.17 207 58865 62529 70806843
Rheumatoid arthritis 127.64 10.17 42 59030 291763 70577609
Off label use 96.76 10.17 308 58764 742752 70126620
Synovitis 93.98 10.17 3 59069 129225 70740147
Renal failure 88.14 10.17 351 58721 188719 70680653
Drug ineffective 70.76 10.17 476 58596 939276 69930096
Contraindicated product administered 69.07 10.17 14 59058 134598 70734774
Drug abuse 66.46 10.17 20 59052 147236 70722136
Hyperlipidaemia 65.85 10.17 90 58982 23773 70845599
Hepatic steatosis 62.72 10.17 106 58966 33707 70835665
International normalised ratio increased 62.64 10.17 178 58894 80548 70788824
Treatment failure 62.52 10.17 21 59051 144121 70725251
Hand deformity 56.50 10.17 4 59068 86478 70782894
Glycosylated haemoglobin increased 56.38 10.17 71 59001 17320 70852052
Pulmonary valve disease 55.74 10.17 17 59055 270 70869102
Infusion related reaction 55.08 10.17 50 59022 197484 70671888
Drug interaction 52.80 10.17 517 58555 380924 70488448
Pericardial disease 52.48 10.17 19 59053 524 70868848
Dyslipidaemia 52.20 10.17 52 59020 9808 70859564
Glossodynia 51.16 10.17 6 59066 86481 70782891
Maternal exposure during pregnancy 49.68 10.17 17 59055 115328 70754044
Systemic lupus erythematosus 49.44 10.17 12 59060 101890 70767482
Therapeutic product effect decreased 49.21 10.17 29 59043 142989 70726383
Blood glucose increased 48.59 10.17 192 58880 102790 70766582
Pemphigus 48.52 10.17 6 59066 83030 70786342
Myopathy 46.60 10.17 67 59005 18545 70850827
Mitral valve disease 45.14 10.17 29 59043 2911 70866461
Drug-induced liver injury 43.79 10.17 124 58948 55989 70813383
Confabulation 43.76 10.17 16 59056 454 70868918
Stenosis 43.46 10.17 25 59047 2056 70867316
Acute myocardial infarction 42.90 10.17 146 58926 72741 70796631
Joint swelling 42.69 10.17 92 58980 253119 70616253
Diabetes mellitus inadequate control 40.69 10.17 70 59002 22575 70846797
Infection 40.37 10.17 71 59001 210714 70658658
Renal impairment 39.85 10.17 230 58842 143707 70725665
Physical examination abnormal 39.28 10.17 13 59059 272 70869100
Apolipoprotein A-I decreased 38.45 10.17 8 59064 21 70869351
Ependymoma 36.08 10.17 10 59062 111 70869261
Hypersensitivity 35.90 10.17 87 58985 229725 70639647
Wound 35.43 10.17 19 59053 98713 70770659
Gamma-glutamyltransferase increased 34.77 10.17 107 58965 50578 70818794
Diabetic metabolic decompensation 34.70 10.17 25 59047 3027 70866345
Cardiac failure congestive 34.01 10.17 211 58861 135246 70734126
Hepatic function abnormal 33.88 10.17 129 58943 67867 70801505
Jaundice 33.65 10.17 105 58967 50003 70819369
Fibrillary glomerulonephritis 33.64 10.17 8 59064 45 70869327
Toxicity to various agents 33.61 10.17 184 58888 381988 70487384
Skin weeping 33.02 10.17 15 59057 750 70868622
Cardiac discomfort 32.57 10.17 17 59055 1154 70868218
Pericarditis 32.35 10.17 15 59057 84690 70784682
Arthropathy 32.06 10.17 47 59025 150010 70719362
Rectosigmoid cancer 31.82 10.17 11 59061 264 70869108
Cholelithiasis 31.60 10.17 99 58973 47241 70822131
Fall 30.75 10.17 530 58542 443566 70425806
Euglycaemic diabetic ketoacidosis 30.55 10.17 31 59041 5976 70863396
Blood triglycerides abnormal 30.45 10.17 12 59060 420 70868952
Hypoglycaemia 30.29 10.17 157 58915 94207 70775165
Lichen nitidus 30.08 10.17 8 59064 75 70869297
Blood creatinine increased 30 10.17 213 58859 142788 70726584
Metabolic syndrome 29.81 10.17 21 59051 2454 70866918
Rheumatoid factor positive 29.53 10.17 3 59069 48397 70820975
Hepatorenal failure 29.29 10.17 16 59056 1191 70868181
Pancreatic neoplasm 29.24 10.17 17 59055 1426 70867946
Asthenia 29.13 10.17 539 58533 457127 70412245
Photosensitivity reaction 28.66 10.17 55 59017 19285 70850087
Erectile dysfunction 28.51 10.17 45 59027 13517 70855855
Myoglobin blood increased 28.06 10.17 22 59050 3025 70866347
Mitral valve incompetence 28.01 10.17 66 59006 26662 70842710
Chromaturia 27.88 10.17 61 59011 23467 70845905
Blood cholesterol increased 27.73 10.17 117 58955 64487 70804885
Lichenoid keratosis 27.07 10.17 23 59049 3540 70865832
Pancreatitis necrotising 26.35 10.17 22 59050 3306 70866066
Cerebrovascular accident 26.30 10.17 207 58865 143263 70726109
Ischaemic cardiomyopathy 26.27 10.17 31 59041 7073 70862299
Low density lipoprotein increased 26.26 10.17 33 59039 8032 70861340
Glycogen storage disease type V 25.35 10.17 6 59066 33 70869339
Lower respiratory tract infection 24.95 10.17 34 59038 111879 70757493
Stomatitis 24.85 10.17 43 59029 128468 70740904
Ectopic gastric mucosa 24.65 10.17 5 59067 11 70869361
Hyperglycaemia 24.62 10.17 113 58959 64559 70804813
Alopecia 24.50 10.17 84 58988 198406 70670966
Product use issue 24.41 10.17 73 58999 179864 70689508
Echocardiogram abnormal 24.32 10.17 17 59055 1962 70867410
Carotid artery stenosis 24.15 10.17 32 59040 8204 70861168
Electrocardiogram Q wave abnormal 24.12 10.17 11 59061 555 70868817
Nephrosclerosis 24.04 10.17 16 59056 1705 70867667
Subacute kidney injury 23.79 10.17 5 59067 14 70869358
Nasopharyngitis 23.57 10.17 100 58972 222106 70647266
Hepatojugular reflux 23.30 10.17 11 59061 601 70868771
Product use in unapproved indication 22.86 10.17 92 58980 207386 70661986
Pulmonary embolism 22.85 10.17 214 58858 155653 70713719
Chronic kidney disease 22.74 10.17 106 58966 60951 70808421
Medulloblastoma 22.40 10.17 7 59065 121 70869251
Ventricular arrhythmia 22.31 10.17 30 59042 7800 70861572
Hepatitis acute 22.30 10.17 41 59031 13921 70855451
Asthma 21.94 10.17 42 59030 120751 70748621
Chest pain 21.18 10.17 310 58762 250950 70618422
Irritable bowel syndrome 21.03 10.17 8 59064 50842 70818530
Intentional overdose 20.86 10.17 31 59041 98404 70770968
Cholestasis 20.77 10.17 87 58985 47785 70821587
Folliculitis 20.67 10.17 5 59067 42565 70826807
Cytomegalovirus infection 20.67 10.17 4 59068 39754 70829618
Left ventricular dysfunction 20.65 10.17 46 59026 17911 70851461
Wheezing 20.60 10.17 29 59043 94141 70775231
Impaired healing 20.50 10.17 19 59053 74355 70795017
Mobility decreased 20.34 10.17 34 59038 102965 70766407
Change of bowel habit 19.98 10.17 17 59055 2622 70866750
Swelling 19.90 10.17 85 58987 188454 70680918
Sleep disorder due to general medical condition, insomnia type 19.88 10.17 3 59069 35729 70833643
Blood cholesterol abnormal 19.80 10.17 18 59054 3030 70866342
Tricuspid valve incompetence 19.77 10.17 45 59027 17772 70851600
Alkalosis hypochloraemic 19.63 10.17 9 59063 460 70868912
Drug intolerance 19.62 10.17 109 58963 225578 70643794
Musculoskeletal stiffness 19.28 10.17 61 59011 147699 70721673
Blood triglycerides decreased 18.84 10.17 7 59065 208 70869164
Chronic cutaneous lupus erythematosus 18.81 10.17 8 59064 341 70869031
Occult blood 18.75 10.17 13 59059 1481 70867891
Kidney fibrosis 18.58 10.17 18 59054 3282 70866090
Bundle branch block left 18.49 10.17 32 59040 10367 70859005
Diastolic dysfunction 18.06 10.17 30 59042 9403 70859969
Myotonia 18.04 10.17 7 59065 235 70869137
Coronary artery occlusion 17.92 10.17 38 59034 14307 70855065
Death 17.89 10.17 308 58764 509753 70359619
Dilatation ventricular 17.69 10.17 19 59053 3912 70865460
Narcotic bowel syndrome 17.68 10.17 7 59065 248 70869124
Diabetic ketoacidosis 17.56 10.17 62 59010 31450 70837922
Angina unstable 17.48 10.17 40 59032 15853 70853519
Productive cough 17.26 10.17 24 59048 78313 70791059
Dialysis 17.19 10.17 42 59030 17360 70852012
Testicular oedema 17.18 10.17 5 59067 67 70869305
Normochromic normocytic anaemia 17.17 10.17 25 59047 6998 70862374
Mucosal dryness 17.10 10.17 17 59055 3199 70866173
Diabetes mellitus 16.85 10.17 110 58962 71714 70797658
Arterial spasm 16.62 10.17 6 59066 164 70869208
Hypertonic bladder 16.52 10.17 18 59054 3765 70865607
Multiple fractures 16.42 10.17 24 59048 6741 70862631
Ocular icterus 16.24 10.17 21 59051 5256 70864116
Cardiomegaly 16.08 10.17 51 59021 24494 70844878
Psoriasis 15.88 10.17 138 58934 98295 70771077
Haemorrhagic fever 15.72 10.17 4 59068 31 70869341
Xanthoma 15.67 10.17 6 59066 194 70869178
Discomfort 15.60 10.17 41 59031 105395 70763977
Chondrocalcinosis 15.60 10.17 9 59063 744 70868628
Rhinalgia 15.56 10.17 11 59061 1293 70868079
Rales 15.50 10.17 40 59032 17095 70852277
Malignant neoplasm progression 15.37 10.17 51 59021 121688 70747684
Glomerular filtration rate decreased 15.35 10.17 45 59027 20711 70848661
Anticoagulation drug level above therapeutic 15.19 10.17 16 59056 3222 70866150
Thirst 15.16 10.17 36 59036 14613 70854759
Anaemia macrocytic 15.07 10.17 20 59052 5135 70864237
Hepatic fibrosis 14.87 10.17 22 59050 6245 70863127
Catheter site thrombosis 14.76 10.17 6 59066 228 70869144
Intentional product use issue 14.71 10.17 51 59021 120091 70749281
Aspartate aminotransferase increased 14.63 10.17 166 58906 126812 70742560
Oedema peripheral 14.60 10.17 269 58803 227822 70641550
Hepatitis 14.56 10.17 81 58991 49899 70819473
Blood urea increased 14.46 10.17 76 58996 45833 70823539
Platelet count decreased 14.46 10.17 88 58984 178134 70691238
Muscle injury 14.41 10.17 7 59065 38487 70830885
Polymyositis 14.38 10.17 15 59057 2986 70866386
Hepatocellular injury 14.31 10.17 76 58996 46015 70823357
Systolic dysfunction 14.31 10.17 16 59056 3445 70865927
Orthopnoea 14.24 10.17 27 59045 9381 70859991
Arteriosclerosis 14.20 10.17 38 59034 16600 70852772
Essential hypertension 14.11 10.17 20 59052 5464 70863908
Electrocardiogram abnormal 14.07 10.17 35 59037 14629 70854743
Libido disorder 14.04 10.17 6 59066 259 70869113
Supraventricular tachycardia 13.88 10.17 42 59030 19668 70849704
Exposure during pregnancy 13.84 10.17 33 59039 87684 70781688
Congestive hepatopathy 13.79 10.17 17 59055 4057 70865315
Vulvovaginal burning sensation 13.78 10.17 10 59062 1224 70868148
Acute coronary syndrome 13.41 10.17 42 59030 20037 70849335
Proteinuria 13.23 10.17 54 59018 29320 70840052
Carotid arteriosclerosis 13.22 10.17 13 59059 2414 70866958
Angina pectoris 13.17 10.17 77 58995 48306 70821066
Diabetic neuropathy 13.10 10.17 20 59052 5838 70863534
Abdominal discomfort 13.07 10.17 115 58957 214543 70654829
Coronary artery bypass 12.94 10.17 20 59052 5900 70863472
Diet noncompliance 12.93 10.17 7 59065 512 70868860
Therapy non-responder 12.90 10.17 28 59044 76887 70792485
Intraocular pressure decreased 12.85 10.17 5 59067 169 70869203
Meningitis streptococcal 12.80 10.17 5 59067 171 70869201
Blood glucose abnormal 12.74 10.17 26 59046 9531 70859841
Left ventricular hypertrophy 12.72 10.17 27 59045 10175 70859197
Glycosuria 12.69 10.17 12 59060 2123 70867249
Anhedonia 12.68 10.17 33 59039 14180 70855192
Therapeutic product effect incomplete 12.67 10.17 54 59018 119828 70749544
Aortic arteriosclerosis 12.43 10.17 23 59049 7846 70861526
Cardiomyopathy 12.29 10.17 49 59023 26324 70843048
Pain 12.26 10.17 415 58657 628401 70240971
Grandiosity 12.20 10.17 7 59065 573 70868799
Lipase increased 12.19 10.17 34 59038 15212 70854160
Blood glucose decreased 12.16 10.17 46 59026 24113 70845259
Intra-abdominal haematoma 12.09 10.17 13 59059 2679 70866693
Lipids increased 12.08 10.17 10 59062 1485 70867887
Myositis 12.06 10.17 37 59035 17452 70851920
Ketonuria 12.05 10.17 9 59063 1151 70868221
Radicular pain 12.05 10.17 6 59066 369 70869003
Liver disorder 11.92 10.17 90 58982 61478 70807894
Coagulation test abnormal 11.71 10.17 9 59063 1201 70868171
Pericardial effusion 11.71 10.17 67 59005 41709 70827663
Loss of bladder sensation 11.57 10.17 4 59068 96 70869276
Renal tubular necrosis 11.57 10.17 44 59028 23127 70846245
Arthralgia 11.57 10.17 325 58747 503065 70366307
Palatal oedema 11.53 10.17 9 59063 1229 70868143
Eosinophilia 11.52 10.17 65 59007 40254 70829118
Drug resistance 11.45 10.17 9 59063 38181 70831191
Blister 11.43 10.17 44 59028 100482 70768890
Glutamate dehydrogenase increased 11.39 10.17 3 59069 27 70869345
Auditory disorder 11.38 10.17 6 59066 416 70868956
Transient ischaemic attack 11.16 10.17 71 59001 45873 70823499
Cardiac disorder 11.03 10.17 86 58986 59329 70810043
Urticaria pigmentosa 11.02 10.17 3 59069 31 70869341
Ureteric cancer recurrent 11.02 10.17 3 59069 31 70869341
Vulvovaginal pruritus 11.00 10.17 11 59061 2085 70867287
Gastrointestinal haemorrhage 10.96 10.17 168 58904 137240 70732132
Thrombocytopenia 10.93 10.17 137 58935 238973 70630399
Sleep apnoea syndrome 10.89 10.17 55 59017 32658 70836714
Diabetic gastroparesis 10.88 10.17 5 59067 257 70869115
Nephrotic syndrome 10.85 10.17 26 59046 10614 70858758
Renin decreased 10.83 10.17 4 59068 117 70869255
Recurrence of neuromuscular blockade 10.72 10.17 5 59067 266 70869106
Cardioactive drug level increased 10.69 10.17 14 59058 3548 70865824
Hypothyroidism 10.68 10.17 70 59002 45685 70823687
Rash 10.64 10.17 334 58738 510228 70359144
Shigella infection 10.61 10.17 3 59069 36 70869336
Blood potassium increased 10.59 10.17 48 59024 27278 70842094
Retinal vein occlusion 10.54 10.17 13 59059 3103 70866269
Myocardial ischaemia 10.51 10.17 44 59028 24156 70845216
Bipolar disorder 10.50 10.17 21 59051 7587 70861785
Neurotoxicity 10.32 10.17 6 59066 29820 70839552
Muscle spasms 10.31 10.17 183 58889 153863 70715509
Fanconi syndrome 10.30 10.17 12 59060 2701 70866671
Device dislocation 10.25 10.17 3 59069 22504 70846868
Fibromyalgia 10.21 10.17 15 59057 47859 70821513

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AB05 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Fibrates
ATC C10BA03 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
Combinations of various lipid modifying agents
ATC C10BA04 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
Combinations of various lipid modifying agents
ATC C10BA09 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
Combinations of various lipid modifying agents
ATC C10BA12 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
Combinations of various lipid modifying agents
FDA CS M0199111 PPAR alpha
FDA MoA N0000175375 Peroxisome Proliferator-activated Receptor alpha Agonists
FDA EPC N0000175596 Peroxisome Proliferator Receptor alpha Agonist
CHEBI has role CHEBI:35679 antilipemic drugs
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
CHEBI has role CHEBI:176497 geroprotectors
MeSH PA D000963 Antimetabolites
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D057847 Lipid Regulating Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Hyperlipidemia indication 55822004 DOID:1168
Hypoalphalipoproteinemia indication 190785000
Familial hypercholesterolemia - heterozygous indication 238079002
Mixed hyperlipidemia indication 267434003
Hypertriglyceridemia indication 302870006
Agranulocytosis contraindication 17182001 DOID:12987
Myositis contraindication 26889001 DOID:633
Primary biliary cirrhosis contraindication 31712002 DOID:12236
Disorder of gallbladder contraindication 39621005 DOID:0060262
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Leukopenia contraindication 84828003 DOID:615
Disorder of muscle contraindication 129565002 DOID:423
Liver function tests abnormal contraindication 166603001
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Rhabdomyolysis contraindication 240131006
Calculus in biliary tract contraindication 266474003
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Thromboembolic disorder contraindication 371039008
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
145MG TRICOR ABBVIE N021656 Nov. 5, 2004 RX TABLET ORAL 7320802 Feb. 21, 2023 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
48MG TRICOR ABBVIE N021656 Nov. 5, 2004 RX TABLET ORAL 7320802 Feb. 21, 2023 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
120MG FENOGLIDE SALIX N022118 Aug. 10, 2007 RX TABLET ORAL 8124125 Oct. 1, 2024 FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
120MG FENOGLIDE SALIX N022118 Aug. 10, 2007 RX TABLET ORAL 8481078 Oct. 1, 2024 USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
40MG FENOGLIDE SALIX N022118 Aug. 10, 2007 RX TABLET ORAL 8124125 Oct. 1, 2024 FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
40MG FENOGLIDE SALIX N022118 Aug. 10, 2007 RX TABLET ORAL 8481078 Oct. 1, 2024 USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
30MG ANTARA (MICRONIZED) LUPIN N021695 Oct. 18, 2013 DISCN CAPSULE ORAL 8026281 April 22, 2025 TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
30MG ANTARA (MICRONIZED) LUPIN N021695 Oct. 18, 2013 DISCN CAPSULE ORAL 8026281 April 22, 2025 TREATING SEVERE HYPERTRIGLYCERIDEMIA
90MG ANTARA (MICRONIZED) LUPIN N021695 Oct. 18, 2013 RX CAPSULE ORAL 8026281 April 22, 2025 TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
90MG ANTARA (MICRONIZED) LUPIN N021695 Oct. 18, 2013 RX CAPSULE ORAL 8026281 April 22, 2025 TREATING SEVERE HYPERTRIGLYCERIDEMIA
90MG ANTARA (MICRONIZED) LUPIN N021695 Oct. 18, 2013 RX CAPSULE ORAL 9314447 May 31, 2033 TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
90MG ANTARA (MICRONIZED) LUPIN N021695 Oct. 18, 2013 RX CAPSULE ORAL 9314447 May 31, 2033 TREATING SEVERE HYPERTRIGLYCERIDEMIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor AGONIST IC50 6 CHEMBL CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.22 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 5.91 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 4.33 DRUG MATRIX
Beta-3 adrenergic receptor GPCR Ki 4.03 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.16 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.49 DRUG MATRIX
Acetylcholinesterase Enzyme IC50 4.81 DRUG MATRIX
Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor EC50 6.24 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 4.67 DRUG MATRIX
Fatty acid-binding protein, liver Unclassified Kd 7.74 CHEMBL
Cruzipain Enzyme IC50 4.21 CHEMBL

External reference:

IDSource
4021098 VUID
N0000148554 NUI
D00565 KEGG_DRUG
4021098 VANDF
C0033228 UMLSCUI
CHEBI:5001 CHEBI
CHEMBL672 ChEMBL_ID
DB01039 DRUGBANK_ID
D011345 MESH_DESCRIPTOR_UI
3339 PUBCHEM_CID
7186 IUPHAR_LIGAND_ID
3996 INN_ID
U202363UOS UNII
8703 RXNORM
12032 MMSL
44688 MMSL
d04286 MMSL
003789 NDDF
108603001 SNOMEDCT_US
386879008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tricor HUMAN PRESCRIPTION DRUG LABEL 1 0074-3173 TABLET 48 mg ORAL NDA 28 sections
Tricor HUMAN PRESCRIPTION DRUG LABEL 1 0074-3189 TABLET 145 mg ORAL NDA 28 sections
Tricor HUMAN PRESCRIPTION DRUG LABEL 1 0074-6122 TABLET 48 mg ORAL NDA 28 sections
Tricor HUMAN PRESCRIPTION DRUG LABEL 1 0074-6123 TABLET 145 mg ORAL NDA 28 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0115-0511 CAPSULE 67 mg ORAL ANDA 12 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0115-0522 CAPSULE 134 mg ORAL ANDA 12 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0115-0533 CAPSULE 200 mg ORAL ANDA 12 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0115-1522 TABLET 40 mg ORAL NDA AUTHORIZED GENERIC 26 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0115-1523 TABLET 120 mg ORAL NDA AUTHORIZED GENERIC 26 sections
FENOFIBRATE HUMAN PRESCRIPTION DRUG LABEL 1 0115-5511 TABLET 54 mg ORAL ANDA 23 sections
FENOFIBRATE HUMAN PRESCRIPTION DRUG LABEL 1 0115-5522 TABLET 160 mg ORAL ANDA 23 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-3065 TABLET, FILM COATED 48 mg ORAL ANDA 26 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-3066 TABLET, FILM COATED 145 mg ORAL ANDA 26 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-4390 TABLET 40 mg ORAL ANDA 27 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-4391 TABLET 120 mg ORAL ANDA 27 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-7100 TABLET, FILM COATED 54 mg ORAL ANDA 26 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-7101 TABLET, FILM COATED 160 mg ORAL ANDA 26 sections
fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8270 TABLET 160 mg ORAL ANDA 26 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6810 TABLET 160 mg ORAL ANDA 24 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 0904-7128 TABLET 160 mg ORAL ANDA 24 sections
FENOFIBRATE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7161 TABLET 145 mg ORAL ANDA 25 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 13668-438 CAPSULE 200 mg ORAL ANDA 14 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 13668-438 CAPSULE 200 mg ORAL ANDA 14 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 13668-438 CAPSULE 200 mg ORAL ANDA 14 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 13668-439 CAPSULE 134 mg ORAL ANDA 14 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 13668-439 CAPSULE 134 mg ORAL ANDA 14 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 13668-439 CAPSULE 134 mg ORAL ANDA 14 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 13668-440 CAPSULE 67 mg ORAL ANDA 14 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 13668-440 CAPSULE 67 mg ORAL ANDA 14 sections
Fenofibrate HUMAN PRESCRIPTION DRUG LABEL 1 13668-440 CAPSULE 67 mg ORAL ANDA 14 sections